ଗୁସେଲକୁମାବ

ଗୁସେଲକୁମାବ
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL23
Clinical data
Trade names	Tremfya
AHFS/Drugs.com	monograph
MedlinePlus	a617036
data	US DailyMed: Guselkumab;
Pregnancy; category	AU: B1 ; ;
Routes of; administration	Subcutaneous
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C6402H9864N1676O1994S42
Molar mass	୧,୪୩,୫୬୧.୫୯ g·mol−1

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Guselkumab

ଗୁସେଲକୁମାବ, ବେପାର ନାମ ଟ୍ରେମଫ୍ୟା, ହେଉଛି ଏକ ଔଷଧ ଯାହା ପ୍ଲେକ୍ ସୋରିଆସିସ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ^[୬] ଏହା ମଧ୍ୟମରୁ ଗମ୍ଭୀର ଧରଣର ରୋଗ ପାଇଁ ଦିଆଯାଏ ।^[୫] ଚର୍ମ ତଳେ ଇଞ୍ଜେକସନ ଆକାରରେ ଏହା ଦିଆଯାଏ | ^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଉପର ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ ହୋଇପାରେ ।^[୫] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ, ମୁଣ୍ଡବିନ୍ଧା, ଗଣ୍ଠି ଯନ୍ତ୍ରଣା, ଯକୃତ ସମସ୍ୟା ଏବଂ ଟିକାଗୁଡ଼ିକର ପ୍ରଭାବ ହ୍ରାସ ହୋଇପାରେ ।^[୭] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୭] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଇଣ୍ଟରଲୁକିନ-୨୩କୁ ସଂଲଗ୍ନ ହୁଏ ଏବଂ ତାକୁ ଅବରୋଧ କରେ ।^[୫]

୨୦୧୭ ମସିହାରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଗୁସେଲକୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୭] ^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ମସିହା ସୁଦ୍ଧା ପ୍ରତି ୧୦୦ ମିଗ୍ରା ଗୁସେଲକୁମାବ ନିମନ୍ତେ ୨,୨୫୦ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହେଉଥିଲା ।^[୮] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୧୧,୬୦୦ ଡଲାର ଥିଲା ।^[୯]

ଆଧାର[ସମ୍ପାଦନା]

↑ "Tremfya (Guselkumab) Australian Product Information". Department of Health, Therapeutic Goods Administration. The Australian Government. Archived from the original on 2021-06-13. Retrieved 2021-10-10.
↑ "European Medicines Agency". European Medicines Agency {EMA). Retrieved 12 June 2021.
↑ "Tremfya 100 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 1 November 2020. Archived from the original on 13 June 2021. Retrieved 12 June 2021.
↑ "Tremfya- guselkumab injection". DailyMed. Archived from the original on 28 January 2021. Retrieved 22 January 2021.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Tremfya". Archived from the original on 22 November 2021. Retrieved 9 December 2021.
↑ "Guselkumab". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. June 2018. PMID 31643594.
↑ ^୭.୦ ^୭.୧ ^୭.୨ "Guselkumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 September 2021. Retrieved 9 December 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1302. ISBN 978-0857114105.
↑ "Guselkumab Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 9 December 2021.

[1] "Tremfya (Guselkumab) Australian Product Information". Department of Health, Therapeutic Goods Administration. The Australian Government. Archived from the original on 2021-06-13. Retrieved 2021-10-10.

[2] "European Medicines Agency". European Medicines Agency {EMA). Retrieved 12 June 2021.

[3] "Tremfya 100 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC)". (emc). 1 November 2020. Archived from the original on 13 June 2021. Retrieved 12 June 2021.

[Tremfya_FDA_label-4] "Tremfya- guselkumab injection". DailyMed. Archived from the original on 28 January 2021. Retrieved 22 January 2021.

[EPAR2021-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Tremfya". Archived from the original on 22 November 2021. Retrieved 9 December 2021.

[Liv2021-6] "Guselkumab". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases. June 2018. PMID 31643594.

[AHFS2021-7] ୭.୦ ^୭.୧ ^୭.୨ "Guselkumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 September 2021. Retrieved 9 December 2021.

[BNF81-8] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1302. ISBN 978-0857114105.

[9] "Guselkumab Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 9 December 2021.

[୧]

[୩]

[୪]

[୨]

[୫]

[୬]

[୭]

[୮]

[୯]